In This Issue

263 In This Issue of Diabetes Care

Perspectives in Care

265 Red and Processed Meats and Health Risks: How Strong Is the Evidence?
  F. Qian, M.C. Riddle, J. Wylie-Rosett, and F.B. Hu

Commentary

272 How Valid Are the New Hypoglycemia Definitions for Use in Clinical Trials?
  P. Home

Nonalcoholic Fatty Liver Disease in Diabetes

275 Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
  K. Cusi

280 Role of Exercise in Mitigating Pediatric Nonalcoholic Fatty Liver Disease
  J.M. Vittorio and J.E. Lavine

283 Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
  Z.M. Younossi, R.P. Tampi, A. Racila, Y. Qiu, L. Burns, I. Younossi, and F. Nader

290 Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes

298 Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

306 Effects of Exercise in Addition to a Family-Based Lifestyle Intervention Program on Hepatic Fat in Children With Overweight
  I. Labayen, M. Medrano, L. Arenaza, E. Maiz, M. Osés, V. Martínez-Vizcaíno, J.R. Ruiz, and F.B. Ortega

Clinical Care/Education/Nutrition/Psychosocial Research

314 Sex Difference in Effects of Low-Dose Aspirin on Prevention of Dementia in Patients With Type 2 Diabetes: A Long-term Follow-up Study of a Randomized Clinical Trial

321 Superior Long-term Survival for Simultaneous Pancreas-Kidney Transplantation as Renal Replacement Therapy: 30-Year Follow-up of a Nationwide Cohort
  K. Esmeijer, E.K. Hoogeveen, P.J.M. van den Boog, C. Konijn, M.J.K. Mollat, A.G. Boranski, O.M. Dekkers, and J.W. de Fijter, on behalf of the Dutch Transplant Centers

329 Diabetes INSIDE: Improving Population HbA₁c Testing and Targets in Primary Care With a Quality Initiative

337 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA₁c in Andalusia (Spain): PLATEDIAN Study

343 Suicide Risk Assessment in Youth and Young Adults With Type 1 Diabetes

Epidemiology/Health Services Research

349 Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study

358 Plasma and Dietary Linoleic Acid and 3-Year Risk of Type 2 Diabetes After Myocardial Infarction: A Prospective Analysis in the Alpha Omega Cohort

366 Plasma Lipidome and Prediction of Type 2 Diabetes in the Population-Based Malmö Diet and Cancer Cohort

374 Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

382 Mortality Implications of Prediabetes and Diabetes in Older Adults

Emerging Technologies: Data Systems and Devices

389 Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
  S. Charleer, C. De Block, L. Van Huffel, B. Broos, S. Fieuws, F. Nobels, C. Mathieu, and P. Gillard

Pathophysiology/Complications

398 Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes
Benefits of Participating With a Partner in the National Diabetes Prevention Program
N.D. Ritchie, K.I.W. Baucom, and K.A. Sauder

The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE

H. Shao, L. Shi, and V. Fonseca

M.W. Segar, M. Vaduganathan, D.K. McGuire, M. Basit, and A. Pandey

Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
M. Skelin, D. Rahelić, P. Skelin, and M. Lucijanic

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
M.A. Nauck, E. Kreiner, S. Rasmussen, H.A. Saevereid, and J.B. Buse, on behalf of the LEADER Trial Investigators

Comment on Hubbard et al. Prediabetes and Risk for Cardiovascular Disease by Hypertension Status in Black Adults: The Jackson Heart Study. Diabetes Care 2019;42:2322–2329
J. Wu, J.-s. Liu, and L.-q. Kong

Cover: Acrylic painted flower arrangement in Romanian traditional decorated ceramic vase. Credit: mitza. For more information, please visit istockphoto.com.